Discussion Among US adults with T2D and ASCVD, combination therapy with SGLT2i and GLP-1RA was associated with reduced incidence rates and risks of CV outcomes, including ischemic stroke, MI, 3-point MACE, and 5-point MACE, compared with SGLT2i alone
The timing hypothesis: hormone therapy started within 10 years of the final menstrual period vs more than 10 years out
(iv) an increase in portal serum level of GLP-1 and PYY
Eating Small, Frequent Portions: Since your stomach stays full longer, large meals can feel uncomfortable
This effect has been noted with GLP-1 receptor agonists as a class and may be further influenced by glucagon receptor agonism
GLP-1 and extra-islet effects